Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Verification of mRNA and protein level expression in FOXA1 siRNA-treated ovarian cancer cells. ( a ) FOXA1 mRNA expression after FOXA1 siRNA transfection. ( b ) Quantification of FOXA1 protein expression. ( c ) Representative Western blot images of FOXA1 and β-actin after FOXA1 siRNA transfection.

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Expressing, Transfection, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and HEYA8 ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Control

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Cell migration, invasion, and wound healing assay to silence of FOXA1 in ovarian cancer cells. ( a ) FOXA1 si decreased the migration ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( b ) FOXA1 si decreased the invasion ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( c ) Representative images of the wound healing assay at 0, 12, 24, 36, and 48 h time points (Left: SK-OV3, Right: HEYA8). ( d ) The quantitative evaluation and statistical analysis of wound area percentage in wound healing assay measured by Image J software. Results are expressed as mean ± SD of five experiments (Left: SK-OV3, Right: HEYA8).

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Migration, Wound Healing Assay, Software

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Comparison of EMT gene expression after treatment with FOXA1 siRNA. ( a ) Changes in EMT gene expression in HEYA8. ( b ) Changes in EMT gene expression in SK-OV3. ( c ) Schematic representation of EMT and MET processes and their key molecular markers.

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Comparison, Gene Expression

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Reduction in chemoresistance following FOXA1 Gene Knockdown. ( a ) Determining IC50 values using carboplatin. ( b ) Atezolizumab cytotoxicity test in SK-OV3 and HEY A8 cells. ( c , d ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without atezolizumab. ( e , f ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without FOXA1 knockdown. ( g , h ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following combined treatment with carboplatin and atezolizumab, with or without FOXA1 knockdown. ( i , j ) Comparison of cell viability in FOXA1-silenced SK-OV3 and HEYA8 cells treated with carboplatin alone or in combination with atezolizumab.

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Knockdown, Comparison

Journal: International Journal of Molecular Sciences

Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

doi: 10.3390/ijms27031194

Figure Lengend Snippet: Immunohistochemical analysis of FOXA1 expression in ovarian cancer patient tissue samples. ( a ) High expression of FOXA1. ( b ) Low expression of FOXA1. ( c ) Malignant tumor patients stratified by stage (I–IV) ( p < 0.05). ( d ) Patients under fifty years old stratified into normal, benign, and tumor groups ( p < 0.05). ( e ) Patients under fifty years old stratified by benign vs. tumor only ( p < 0.05).

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

Techniques: Immunohistochemical staining, Expressing